Australian Brain Bee Challenge WA 2022
St Mary’s Anglican Girls’ School has taken out top prize in the Australian Brain Bee Challenge held at The University...
Continue reading
Research groups:
Dr Tri Bao Le
BSc, PhD Postdoctoral Research FellowDr Tri Bao Le is a post-doctoral scientist in the Precision Nucleic Acid Therapeutics Group led by Associate Professor Rakesh Veedu in the Centre for Molecular Medicine and Innovative Therapeutics (CMMIT) at Murdoch University where he undertook his PhD. His current research supported by the Marvin Caruthers’
Foundation focuses on the development of novel chemically modified antisense oligonucleotides, including thiomorpholino oligonucleotides for tackling a variety of genetic conditions.
Publications
Evaluation of DNA segments in 2′-modified RNA sequences in designing efficient splice switching antisense oligonucleotides (2021)
RSC Advances. 11(23):14029-14035. DOI: 10.1039/d1ra00878a
Novel Disulfide-Bridged Bioresponsive Antisense Oligonucleotide Induces Efficient Splice Modulation in Muscle Myotubes in Vitro (2020)
ACS Omega. 5(29):18035-18039. DOI: 10.1021/acsomega.0c01463
Author Correction: Systematic evaluation of 2′-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro (Scientific Reports, (2019), 9, 1, (6078), 10.1038/s41598-019-42523-0) (2020)
Scientific Reports. 10(1) DOI: 10.1038/s41598-020-63706-0
Antisense Oligonucleotides Targeting Angiogenic Factors as Potential Cancer Therapeutics (2019)
Molecular Therapy - Nucleic Acids. 14:142-157. DOI: 10.1016/j.omtn.2018.11.007
Systematic evaluation of 2′-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro (2019)
Scientific Reports. 9(1) DOI: 10.1038/s41598-019-42523-0
Unlocked nucleic acid modified primer-based enzymatic polymerization assay: Towards allele-specific genotype detection of human platelet antigens (2018)
RSC Advances. 8(57):32770-32774. DOI: 10.1039/c8ra06050a
Self-assembling asymmetric peptide-dendrimer micelles – A platform for effective and versatile in vitro nucleic acid delivery (2018)
Scientific Reports. 8(1) DOI: 10.1038/s41598-018-22902-9
Antisense oligonucleotide modified with serinol nucleic acid (SNA) induces exon skipping in: Mdx myotubes (2017)
RSC Advances. 7(54):34049-34052. DOI: 10.1039/c7ra06091b
Nucleobase-modified antisense oligonucleotides containing 5-(phenyltriazol)-2′-deoxyuridine nucleotides induce exon-skipping: In vitro (2017)
RSC Advances. 7(86):54542-54545. DOI: 10.1039/c7ra10964d
Construction of a bivalent thrombin binding aptamer and its antidote with improved properties (2017)
Molecules. 22(10) DOI: 10.3390/molecules22101770
Novel Chemically-modified DNAzyme targeting Integrin alpha-4 RNA transcript as a potential molecule to reduce inflammation in multiple sclerosis (2017)
Scientific Reports. 7(1) DOI: 10.1038/s41598-017-01559-w
Rational Design of Short Locked Nucleic Acid-Modified 2′-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro (2017)
Molecular Therapy - Nucleic Acids. 9:155-161. DOI: 10.1016/j.omtn.2017.09.002
Investigation of twisted intercalating nucleic acid (TINA)-modified antisense oligonucleotides for splice modulation by induced exon-skipping: In vitro (2016)
RSC Advances. 6(97):95169-95172. DOI: 10.1039/c6ra22346j
Evaluation of anhydrohexitol nucleic acid, cyclohexenyl nucleic acid and d-altritol nucleic acid-modified 2′-O-methyl RNA mixmer antisense oligonucleotides for exon skipping in vitro (2016)
Chemical Communications. 52(92):13467-13470. DOI: 10.1039/c6cc07447b
Antisense oligonucleotide development for the treatment of muscular dystrophies (2016)
Expert Opinion on Orphan Drugs. 4(2):139-152. DOI: 10.1517/21678707.2016.1122517
Synthesis of a Morpholino Nucleic Acid (MNA)-uridine phosphoramidite, and exon skipping using MNA/2′-O-methyl mixmer antisense oligonucleotide (2016)
Molecules. 21(11) DOI: 10.3390/molecules21111582
Downregulation of vascular endothelial growth factor enhances chemosensitivity by induction of apoptosis in hepatocellular carcinoma cells (2015)
Cell Journal. 17(2):273-287.
Latest news
Keep informed with our latest updates.